• Calpeptin and Extracellular Vesicle Research

  2026-10-12

  McNamee et al. reported that several pharmacological interventions, including Calpeptin, reduced extracellular-vesicle release from triple-negative breast cancer models. The study supports a role for multiple EV populations in transferring aggressive traits, but its findings do not establish that Calpeptin’s effects are specific to calpain inhibition or applicable to patients, pulmonary fibrosis, or other disease settings.

• AKTIP in Fibrolamellar Carcinoma: Evidence Review

  2026-10-12

  A cautious editorial reading of Wang et al. (2025) identifies AKTIP as a computationally prioritized biomarker candidate for fibrolamellar carcinoma, while emphasizing that public-dataset analysis, limited molecular validation, and in silico compound nomination do not establish clinical diagnostic, prognostic, or therapeutic utility. The APExBIO reagent is discussed only as separate product information, not as a reagent documented in the study.

• PS Nanoplastics, Cadmium and Intestinal Apoptosis

  2026-10-11

  A source-grounded overview of a 2026 Toxicology study examining whether polystyrene nanoplastic–cadmium co-exposure promotes intestinal apoptosis through the IP3R/Ca2+/STAT3 signaling axis. The findings support calcium dysregulation as a mechanistic component in the tested models, while model choice, pharmacological specificity and environmental relevance limit broader conclusions.

• Probenecid: MDR, Neuroprotection, and T Cells

  2026-10-10

  A source-grounded overview of Probenecid research, separating supplier-reported evidence on multidrug resistance and cerebral ischemia/reperfusion injury from peer-reviewed findings on CD8+ T-cell metabolism. The article compares evidence strength, explains plausible conceptual applications, and defines limits on interpreting Probenecid as an immunometabolic or neuroprotective tool.

• AMPK, Mitophagy, and Inflammation in Diabetic PDL

  2026-10-09

  This 2026 FASEB Journal study examines how AMPK connects PINK1/Parkin-mediated mitophagy with NLRP3-associated inflammation in periodontal ligament fibroblasts exposed to mechanical loading. Its in vivo and in vitro evidence suggests that high glucose weakens mitochondrial quality control, whereas AMPK activation supports mitophagy and may reduce inflammatory signaling, while remaining limited to preclinical models.

• v-Agatoxin-IVA and N-Type Calcium Channel Blockade

  2026-10-09

  Sidach and Mintz showed that v-Agatoxin-IVA, widely used as a selective P-type calcium channel blocker, can also inhibit neuronal N-type calcium currents at lower affinity. Their findings refine pharmacological channel classification and caution against treating toxin sensitivity as an absolute indicator of channel identity.

• ML133 HCl and the Translational Case for Kir2.1

  2026-10-08

  Kir2.1 is emerging as a mechanistic link between potassium ion transport and pulmonary vascular remodeling. This thought-leadership analysis examines what ML133 HCl can—and cannot—establish in translational research, with emphasis on evidence strength, model selection, orthogonal validation, and the boundary between a useful pharmacological probe and a clinical claim.

• Tiamulin in Psoriasis: What the 2022 Study Shows

  2026-10-08

  The 2022 Journal of Dermatological Science study identified tiamulin fumarate as a small-molecule inhibitor of TNF-α-associated inflammatory responses through high-throughput screening. In keratinocyte and imiquimod-induced mouse models, the compound reduced inflammatory signaling and psoriasis-like dermatitis, but the findings remain preclinical and do not establish clinical efficacy or a direct molecular binding mechanism.

• ML385 and NRF2 Signaling: Evidence and Limits

  2026-10-07

  ML385 is a research-use NRF2 inhibitor used to examine how NRF2-dependent antioxidant signaling influences disease biology. Recent work in inflammatory osteolysis used ML385 alongside genetic and biochemical evidence to test whether kaempferol acts through NRF2. The findings support pathway dependence in that model, but they do not establish clinical efficacy, universal selectivity, or applicability to cancer, ferroptosis, or human disease.

• Phenytoin: A Framework for Sodium-Channel Evidence

  2026-10-07

  Phenytoin research spans voltage-gated sodium channel biology and broader biochemical effects. This evidence-focused guide connects electrophysiology assay design with the reported human serum PON1 inhibition findings while defining appropriate interpretation boundaries.

• Tetracycline: Mechanism, Evidence, and Limits

  2026-10-06

  Tetracycline is a broad-spectrum polyketide antibiotic whose principal activity is reversible bacterial ribosome targeting and inhibition of bacterial protein synthesis. Current evidence supports its microbiological and ribosomal research roles, but the supplied LKB1 lung adenocarcinoma study does not establish tetracycline as a regulator of telomerase or histone lactylation.

• Beyond Calpain Inhibition: From FAK Biology to Translation

  2026-10-06

  The FAISL–calpain 2–FAK axis shows why proteolysis should be treated as a signaling variable rather than a downstream consequence. This thought-leadership article places Calpain Inhibitor II, ALLM within a careful translational framework spanning protease biology, apoptosis, cancer models, evidence boundaries, and biomarker strategy.

• METTL16–SENP3–LTF Drives Ferroptosis Resistance

  2026-10-05

  Wang et al. identify a METTL16–SENP3–LTF signaling axis that links m6A-dependent RNA regulation to iron handling and ferroptosis resistance in hepatocellular carcinoma. The study’s multi-model evidence suggests that this pathway may provide a biomarker framework and a mechanistic basis for sensitizing HCC to ferroptosis-oriented therapeutic strategies.

• Sex Differences in Angiotensin II Hypertension

  2026-10-05

  Xue, Pamidimukkala, and Hay used conscious-mouse telemetry, gonadectomy, baroreflex assessment, and ganglionic blockade to show that angiotensin II produced a substantially larger pressor response in males than females. The study’s main contribution is linking sex-dependent blood-pressure phenotypes with baroreflex and sympathetic mechanisms while defining important limits for interpretation and translation.

• Probenecid: Evidence, Mechanisms, and Limits

  2026-10-04

  Probenecid, also known as 4-(dipropylsulfamoyl)benzoic acid, has been described in research contexts involving organic anion transport, multidrug resistance, pannexin-1 signaling, and cerebral ischemia/reperfusion injury. This overview compares those reported findings with a 2024 study of CD28–ARS2–PKM alternative splicing in CD8+ T cells, while separating direct evidence from mechanistic speculation and identifying important limits on interpretation.

7854 records 1/524 page Next 12345 下5页 Last page